Future growth expectations in sales/revenue/volumes?

Growth expected to start kicking in FY25 with revival in demand from major pharma players. FY24 anticipated to remain moderate with slower growth. Huge growth opportunities as the company moves deeper into the pharmaceutical market. Plans to commercialize P-10 plant by end of FY24 and P-11 plant by FY25 to widen product basket. Expansion includes acquiring adjacent land (25,000 sq. meters) to existing facility for future growth. Focus on import substitution, primarily serving domestic market rather than exports. Recovery seen in inorganic chemicals segment (bromide), with operations at 75-80%

Future growth expectations in earnings/operating earnings/profits/EPS?

Growth is expected to start picking up from FY25, driven by revival in demand from major pharma players. FY24 is anticipated to remain moderate with no specific guidance given for performance. The company aims for long-term sustainable growth via meaningful product and capacity investments. Expansion through commissioning of new production plants (P-10 by end FY24, P-11 by FY25) targeting pharma intermediates is underway. Focus on import substitution for the domestic market, especially in pharma chemicals, with limited exports expected. Management cautions against evaluating business

Current/ Expected Orderbook/ Pending Orders?

The bromide industry, which lies within Chemcon's business, has picked up with the company currently operating at nearly 75% to 80% of its capacity. The company has enough order books currently, indicating a healthy pipeline of orders. No specific numerical value for the current or expected orderbook/pending orders has been disclosed during the call. Demand for certain products like HMDS and CMIC has underperformed recently but there is hope for revival in coming quarters. Chemcon is focusing on import substitution in pharma intermediates, which could support future order inflows. Overall, the

Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. No queries or responses during the earnings call indicate intentions for raising capital. Discussions primarily focus on operations, product developments, margins, land acquisition, and expansion plans. CAPEX details were referred to be provided by Investor Relations (SGA), but no explicit mention of funding sources. Management did not provide any guidance on capital raising activities.

Any current/future capex/capital investment/strategic investment?

The company has recently acquired an adjoining land parcel of about 25,000 square meters adjacent to their existing 50,000 square meter facility at Manjusar, expanding land availability by 50% for future expansions. Plans to commercialize the P-10 plant by the end of FY24; the P-11 plant is under construction with commissioning targeted in FY25. The new plants (P-10 and P-11) aim to manufacture a new range of pharma intermediates to widen the product basket. No specific CAPEX figures disclosed in the call; detailed CAPEX information to be provided by SGA, the investor relations advisors. Ongoi

Chemcon Speciality Chemicals LtdQ2 FY24Chemicals & Petrochemicals

Chemcon Speciality Chemicals Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹181.84P/E: 23.6Market Cap: ₹666 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

Growth expected to start kicking in FY25 with revival in demand from major pharma players.
FY24 anticipated to remain moderate with slower growth.
Huge growth opportunities as the company moves deeper into the pharmaceutical market.
Plans to commercialize P-10 plant by end of FY24 and P-11 plant by FY25 to widen product basket.
Expansion includes acquiring adjacent land (25,000 sq. meters) to existing facility for future growth.
Focus on import substitution, primarily serving domestic market rather than exports.
Recovery seen in inorganic chemicals segment (bromide), with operations at 75-80% capacity and healthy order books.
Volume growth noted: organic chemicals volume increased from 1,502 metric tons (H1 FY23) to 2,398 metric tons (H1 FY24).
Management cautious on guidance but optimistic over medium to long-term growth prospects.

Margin guidance

Category 3

Growth is expected to start picking up from FY25, driven by revival in demand from major pharma players.
FY24 is anticipated to remain moderate with no specific guidance given for performance.
The company aims for long-term sustainable growth via meaningful product and capacity investments.
Expansion through commissioning of new production plants (P-10 by end FY24, P-11 by FY25) targeting pharma intermediates is underway.
Focus on import substitution for the domestic market, especially in pharma chemicals, with limited exports expected.
Management cautions against evaluating business purely on margin percentage due to volatile raw material and finished product prices.
EBIDTA and PAT margins declined in recent quarters due to pricing headwinds but the inorganic chemical segment has recovered well.
No explicit EPS or profit guidance provided in the call.

See what Chemcon Speciality Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity.
No queries or responses during the earnings call indicate intentions for raising capital.
Discussions primarily focus on operations, product developments, margins, land acquisition, and expansion plans.
CAPEX details were referred to be provided by Investor Relations (SGA), but no explicit mention of funding sources.
Management did not provide any guidance on capital raising activities.

Order book

Yes

The bromide industry, which lies within Chemcon's business, has picked up with the company currently operating at nearly 75% to 80% of its capacity.
The company has enough order books currently, indicating a healthy pipeline of orders.
No specific numerical value for the current or expected orderbook/pending orders has been disclosed during the call.
Demand for certain products like HMDS and CMIC has underperformed recently but there is hope for revival in coming quarters.
Chemcon is focusing on import substitution in pharma intermediates, which could support future order inflows.
Overall, the company's order book position appears stable with solid demand especially in bromide chemicals, though certain segments are cyclical and fluctuating.

See what Chemcon Speciality Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has recently acquired an adjoining land parcel of about 25,000 square meters adjacent to their existing 50,000 square meter facility at Manjusar, expanding land availability by 50% for future expansions.
Plans to commercialize the P-10 plant by the end of FY24; the P-11 plant is under construction with commissioning targeted in FY25.
The new plants (P-10 and P-11) aim to manufacture a new range of pharma intermediates to widen the product basket.
No specific CAPEX figures disclosed in the call; detailed CAPEX information to be provided by SGA, the investor relations advisors.
Ongoing investments focused on increasing product offerings and facilitating sustainable long-term growth, especially targeting import substitution in the pharma market.

Track Chemcon Speciality Chemicals Ltd — get its next earnings analysis in your feed

How does Chemcon Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisChemcon Speciality Chemicals Ltd

Rev 4Mar 3

See where Chemcon Speciality Chemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Chemcon Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare Chemcon Speciality Chemicals Ltd against every Chemicals & Petrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Chemcon Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Neogen Chemicals Ltd (Q2 FY27)
Consolidated: ₹295.96 crore (up from ₹208.66 crore in Q3 FY25) . Key results statement takeaways from Neogen Chemicals Ltd's Q2 FY27 results statement — and how
Mahickra Chemicals Ltd (Q2 FY27)
682 million, a 34% year-on-year increase. Key results statement takeaways from Mahickra Chemicals Ltd's Q2 FY27 results statement — and how it ranks against sec
Vishnu Chemicals Ltd (Q2 FY27)
2,837.7 lakhs increase (~7.07% growth YoY). Key results statement takeaways from Vishnu Chemicals Ltd's Q2 FY27 results statement — and how it ranks against sec
Yasons Chemex (Q2 FY27)
4,927.35 lakhs for the same period in 2025, indicating a year-on-year decline of about 16.3% (Page 12). Key results statement takeaways from Yasons Chemex Care

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →